110 related articles for article (PubMed ID: 28357122)
1. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation.
Rao SSC
Therap Adv Gastroenterol; 2018; 11():1756284818777945. PubMed ID: 29942351
[TBL] [Abstract][Full Text] [Related]
2. The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics.
Mishra V; Sharma K; Bose A; Maisonneuve P; Visweswariah SS
J Biol Chem; 2024 Jan; 300(1):105505. PubMed ID: 38029963
[TBL] [Abstract][Full Text] [Related]
3. Guanylate cyclase-C Signaling Axis as a theragnostic target in colorectal cancer: a systematic review of literature.
Piroozkhah M; Aghajani A; Jalali P; Shahmoradi A; Piroozkhah M; Tadlili Y; Salehi Z
Front Oncol; 2023; 13():1277265. PubMed ID: 37927469
[TBL] [Abstract][Full Text] [Related]
4. Plecanatide (Trulance) for chronic idiopathic constipation.
Med Lett Drugs Ther; 2017 Apr; 59(1519):66-68. PubMed ID: 28419073
[No Abstract] [Full Text] [Related]
5. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.
DeMicco M; Barrow L; Hickey B; Shailubhai K; Griffin P
Therap Adv Gastroenterol; 2017 Nov; 10(11):837-851. PubMed ID: 29147135
[TBL] [Abstract][Full Text] [Related]
6. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
Weinberg DS; Lin JE; Foster NR; Della'Zanna G; Umar A; Seisler D; Kraft WK; Kastenberg DM; Katz LC; Limburg PJ; Waldman SA
Cancer Prev Res (Phila); 2017 Jun; 10(6):345-354. PubMed ID: 28396341
[TBL] [Abstract][Full Text] [Related]
7. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
Miner PB
Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):71-84. PubMed ID: 31985305
[No Abstract] [Full Text] [Related]
8. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.
Love BL
Am J Med; 2019 May; 132(5):572-575. PubMed ID: 30550753
[TBL] [Abstract][Full Text] [Related]
9. Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders.
Singh R; Zogg H; Ghoshal UC; Ro S
Front Pharmacol; 2022; 13():808195. PubMed ID: 35145413
[TBL] [Abstract][Full Text] [Related]
10. Cyclic peptide drugs approved in the last two decades (2001-2021).
Zhang H; Chen S
RSC Chem Biol; 2022 Jan; 3(1):18-31. PubMed ID: 35128405
[TBL] [Abstract][Full Text] [Related]
11. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
Entezari AA; Snook AE; Waldman SA
Expert Opin Ther Targets; 2021 May; 25(5):335-346. PubMed ID: 34056991
[TBL] [Abstract][Full Text] [Related]
12. Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders.
Sharma A; Rao SSC; Kearns K; Orleck KD; Waldman SA
Aliment Pharmacol Ther; 2021 Jun; 53(12):1250-1267. PubMed ID: 33909919
[TBL] [Abstract][Full Text] [Related]
13. Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation.
Miner PB
Drug Saf; 2019 May; 42(5):603-615. PubMed ID: 30649746
[TBL] [Abstract][Full Text] [Related]
14. Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.
Brancale A; Shailubhai K; Ferla S; Ricci A; Bassetto M; Jacob GS
Pharmacol Res Perspect; 2017 Apr; 5(2):e00295. PubMed ID: 28357122
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
Miner PB
Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
